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a  b  s  t  r  a  c  t
Merozoite  surface  protein  1  (MSP1)  of  Plasmodium  falciparum  has  been  implicated  as  an important  tar-
get  of  acquired  immunity,  and  candidate  components  for a  vaccine  include  polymorphic  epitopes  in  the
N-terminal  polymorphic  block  2  region.  We  designed  a  polyvalent  hybrid  recombinant  protein  incorpo-
rating  sequences  of  the  three  major  allelic  types  of  block  2 together  with  a composite  repeat  sequence  of
one  of  the  types  and  N-terminal  ﬂanking  T cell  epitopes,  and  compared  this  with  a series  of  recombinant
proteins  containing  modular  sub-components  and  similarly  expressed  in Escherichia  coli.  Immunogenicity
of  the  full  polyvalent  hybrid  protein  was  tested  in  both  mice  and  rabbits,  and comparative  immunogenic-lasmodium falciparum
alaria  vaccine
erozoite
ity  studies  of the  sub-component  modules  were  performed  in  mice.  The  full  hybrid protein  induced  high
titre  antibodies  against  each  of  the major  block  2 allelic  types  expressed  as  separate  recombinant  pro-
teins  and  against  a wide  range  of allelic  types  naturally  expressed  by  a panel  of  diverse  P.  falciparum
isolates,  while  the  sub-component  modules  had  partial  antigenic  coverage  as expected.  This  encourages
further  development  and evaluation  of  the  full MSP1  block  2 polyvalent  hybrid  protein  as  a  candidate
blood-stage  component  of  a malaria  vaccine.
© 2011 Elsevier Ltd. Open access under CC BY license.. Introduction
Complex antigenic polymorphisms present a signiﬁcant chal-
enge for design of a vaccine against the malaria parasite
lasmodium falciparum. Although partial protection offered by the
urrent leading malaria vaccine candidate RTS,S appears not to
e compromised by limited polymorphism in the pre-erythrocytic
ircumsporozoite protein [1], the problem of polymorphism is
ikely to be more important for vaccines based on blood-stage
arasite proteins that are targets of naturally acquired immunity
2,3]. The extracellular merozoite that invades erythrocytes is an
mportant target of immunity [4], and a leading vaccine candi-
ate is the most abundant surface component, merozoite surface
rotein 1 (MSP1) which is expressed as a large ∼200 kDa precur-
or that needs to be proteolytically processed to allow merozoite
aturation [5]. Antibodies to several parts of the protein can
nhibit this processing [6], but most research has focused on the
∗ Corresponding author. Tel.: +44 207 927 2312; fax: +44 207 637 4314.
E-mail  addresses: kevin.tetteh@lshtm.ac.uk (K.K.A. Tetteh),
avid.conway@lshtm.ac.uk (D.J. Conway).
1 Tel.: +44 207 927 2331.
264-410X ©  2011 Elsevier Ltd. 
oi:10.1016/j.vaccine.2011.07.106
Open access under CC BY license.C-terminal region, particularly the 19 kDa C-terminal fragment
MSP1-19 [7–10].
Although the N-terminal region of MSP1 has received less
attention, it contains the most highly polymorphic ‘block 2’
sequences that group into three major allelic types (K1-like,
MAD20-like, and R033-like) [11–16], with hybrid alleles occur-
ring rarely [17,18]. The allele frequencies in endemic populations
appear to be under balancing selection [12], and antibodies against
the sequences have been associated with protection from malaria
[11,12,14,19]. Allele-speciﬁc growth inhibition has been reported
with an antibody-dependant cellular inhibition (ADCI) assay [13],
although antibodies alone are not inhibitory except for a report of
activity with one monoclonal antibody [20].
Previously, we  demonstrated how an epitope mapping
approach could be used to characterize the complex antigenic
polymorphism seen in the K1-like block 2 repeat sequences, and
employed this in the design of a single synthetic sequence termed
the K1 Super Repeat (K1SR) [15]. Immunization of mice with this
K1SR antigen elicited a broad antibody repertoire against P. fal-
ciparum isolates bearing diverse K1-like allelic types. Here we
present the design and characterization of a polyvalent hybrid
protein incorporating the K1SR sequence together with K1-like
ﬂanking block 2 sequences, T helper cell epitope sequences near
the junction of blocks 1 and 2, and MAD20-like and R033-like block
2 allele sequences. To investigate the immunogenic contributions
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28, 42, 56 and 70 following a 77 day protocol with one rabbit receiv-812 K.K.A. Tetteh, D.J. Conway
f each module that made up the ﬁnal construct, ﬁve other sub-
omponent constructs were designed and tested for comparative
mmunogenicity. Antibody responses were largely dependent on
he presence of the T helper cell epitopes, and showed expected
ombinations of allele speciﬁcity. Antibodies to the full polyvalent
ybrid protein raised in both mice and rabbits displayed a broad
epertoire with serological coverage against isolates of all allelic
ypes.
. Materials and methods
.1.  Construction of sequences encoding MSP1 block 2 polyvalent
ybrid  proteins
Six  recombinant antigens were constructed, ﬁve of which were
esigned as comparative reagents (antigens 1–5, Fig. 1A and
upplementary Fig. 1) to validate the ﬁnal candidate immunogen
+)T-K1SR-R033-Wellcome (antigen 6, Fig. 1A and Supplementary
ig. 1). The DNA sequence encoding each antigen was generated
sing a modular construction, with each module separated by
estriction enzyme sites (Supplementary Fig. 1).
For  constructs incorporating the K1-like 3D7 module (antigens
 and 3, Fig. 1A), PCR products were ampliﬁed from 3D7 parasite
enomic DNA using the primer pair KTPfK1F1BamH1 (5′-GGGGA-
CCGTAACACATGAAAGTTAT-3′) and KTPfR1Sac1M1 (5′-GGGAG-
TCGCTTGCATCAGCTGGAGG-3′). This module also included the
equence for a conserved T-cell epitope within MSP1 block 1 (T1,
mino acid position 20–39: VTHESYQELVKKLEALEDAV) and a poly-
orphic T-cell epitope (T2, amino acid position 44–63: GLFHKE-
MILNEEEITTKGA) [21], spanning the junction of blocks 1 and 2.
he R033-type block 2 module was ampliﬁed from R033 parasite
enomic DNA using the primer pairs KTPfR033F1Sac1M2 (5′-GGG-
GCTCAAGGATGGAGCAAATACT-3′) and KTPfR033R1Kpn1M2 (5′-
GGGTACCACTTGAATCATCTGAAGG-3′). The Wellcome (MAD20-
ype) module was ampliﬁed from Wellcome parasite genomic
NA using the primer pair KTPfWellF1Kpn1M3 (5′ GGGGTA-
CAATGAAGGAACAAGTGGA-3′) and KTPfWellR2Sma1M3 (5′-
GCCCGGGTTAACTTGAATTATCTGAAGG-3′). All PCR ampliﬁcations
ere performed using Accuzyme High Fidelity DNA Poly-
erase (Bioline Ltd, London, UK) on P. falciparum genomic
NA isolated from cultured parasites using the QIAamp DNA
lood minikit following manufacturer’s instructions (Qiagen,
estSussex, UK).
The  remaining three modules were commercially synthesised
GeneArt, Germany) as codon optimized sequences for E. coli
xpression and cloned into the pG4 shuttle vector. These were: (i)
 3D7 allelic block 2 module that lacked the N-terminal T cell epi-
opes (in antigen 4, Fig. 1A and Supplementary Fig. 1); (ii) the K1SR
odule [15] also lacking the N-terminal T1/T2 T-cell epitopes (in
ntigen 5, Fig. 1A and Supplementary Fig. 1); (iii) the K1SR module
15] integrating the N-terminal T-cell epitopes (in antigen 6, Fig. 1A
nd Supplementary Fig. 1).
.2. Plasmid cloning and recombinant protein expression
All synthetic DNA products were ﬁrst cloned into the pGEM-
 Easy cloning vector plasmid (Promega, UK). Sequence veriﬁed
NA was excised from the relevant clones using module spe-
iﬁc restriction sites and ligated into pGEM-T Easy vector to
erive the completed recombinant constructs. The commercially
ynthesised modules were excised using module speciﬁc restric-
ion sites directly from the pG4 shuttle vector and cloned onto
he pGEM-T backbone to derive the relevant polyvalent con-
tructs. All constructs were sequenced at each stage to ensure
delity of the cloned products with ABI BIGDYE terminator v3.1ine 29 (2011) 7811– 7817
chemistry  using an ABI 3730xl electrophoresis system (Applied
Biosystems, UK).
Each  completed coding region was  excised using BamHI/KpnI
restriction sites for the full polyvalent hybrid protein sequence
(antigen 6), and BamHI/SmaI for the remaining 5 modular poly-
valent sequences (Fig. 1A), before cloning into complementary
digested sites in the pQE30 His-tag expression vector (Qiagen) for
antigens 1–3 or the pET15b His-tag expression vector (Novagen)
for antigens 4–6 (Fig. 1A). Each cloned recombinant plasmid was
transformed into M15  [pREP4] host E. coli strain (Qiagen) for the
pQE30 cloned products or BL21 (DE3) (Stratagene) for the pET15b
cloned products. All constructs were sequenced to ensure complete
ﬁdelity.
For protein expression, isopropyl-ß-d-thiogalactopyranoside
(IPTG) was added to each culture to a ﬁnal concentration of 1 mM
following bacterial culture growth to OD600 of 0.6–1.0. Bacterial
cells were pelleted, resuspended in BugBuster protein extraction
reagent (Novagen, Merck Chemicals International) and incubated at
room temperature for 20 min  on a rolling platform. Cellular debris
was pelleted by centrifugation, and the histidine-tagged protein
puriﬁed from each supernatant following Nickel His-tag afﬁnity
chromatography using Ni-NTA agarose (Qiagen). The stability of
50 g batches of lyophilized full polyvalent hybrid protein was
tested by incubation at −20, 4, 37 and 56 ◦C for a period of three
weeks.
2.3. SDS PAGE and Western blot analysis
The puriﬁed polyvalent hybrid proteins were separated
under reducing conditions by 12% Tris–glycine–SDS PAGE
and electrophoretically transferred to nitrocellulose membrane
(Whatman, UK). Western blots were probed using murine
sera raised to recombinant proteins based on the individual
MSP1 block 2 types [11,15]. Bound antibody was  detected
with horseradish peroxidase-conjugated rabbit anti-mouse sec-
ondary antibody (DAKO), and bands visualized using 5 ml  per
blot of stabilized TMB  (3,3′,5,5′-tetramethylbenzidine) substrate
(Promega, UK).
2.4.  Murine polyclonal sera
Groups  of ﬁve CD-1 outbred mice were immunized (North-
wick Park Institute for Medical Research, UK) with each antigen
formulated in the ImjectAlum adjuvant (Perbio Science, Cheshire,
UK). Each polyvalent hybrid protein was  diluted with phosphate-
buffered saline (PBS) to a concentration of 1 mg  ml−1, and 3
volumes of Imject Alum added and allowed to mix for 30 min at
room temperature. Each antigen–adjuvant mixture was admin-
istered intra-peritoneally, each mouse receiving 50 g protein
per dose in a ﬁnal volume of 200 l. Three doses were admin-
istered at monthly intervals, and blood was collected before
immunization and 2 weeks after each dose (on days 14, 42,
and 70).
2.5.  Rabbit immunizations
The  puriﬁed polyvalent hybrid antigen (+)T-K1SR-R033-
Wellcome  (antigen 6, Fig. 1A) was  used to immunize New Zealand
white rabbits (Pettingill Technology Limited, UK). Five rabbits
received 200 g of puriﬁed protein intramuscularly at days 0, 14,ing adjuvant with PBS only as a control (Freund’s complete adjuvant
was used on day 0 immunization, Freund’s incomplete adjuvant for
boosting immunizations). Test bleeds were taken on days 35, 49 and
63, ﬁnal bleeds were collected on day 77.
K.K.A. Tetteh, D.J. Conway / Vaccine 29 (2011) 7811– 7817 7813
Fig. 1. Composition of the polyvalent hybrid proteins. (A) Schematic diagram of the MSP1 block 2 constructs. Antigen 6 represents the full polyvalent immunogen with
antigens 1–5 representing reagents designed and produced for comparative purposes. Each protein was  expressed in E. coli with an N-terminal (6×)His-tag for puriﬁcation.
(B) Coomassie-stained 12% SDS-PAGE gel showing each of the six puriﬁed proteins (1–6 in lanes from left to right). (C) Puriﬁed polyvalent hybrid proteins demonstrate
expected antigenicity on Western blots probed with murine antisera raised to GST-fusion proteins of MSP1 block 2 allelic antigens: K1 Super Repeat (K1SR), R033 and
W el A. P
g eight
2
i
l
A
D
m
i
u
n
t
p
t
m
(
s
P
f
L
b
a
(
m
p
e
1
e
b
2
i
rellcome. On each blot, lanes 1–6 contain antigens 1–6 shown in the scheme in pan
ave the same pattern as for the anti-K1SR antiserum. The positions of molecular w
.6. Indirect immunoﬂuoresence assay (IFA) of P. falciparum
solates
Ten  P. falciparum isolates were cultured, including 6 with K1-
ike MSP1 block 2 sequences (3D7, T9/96, T9/102, D6, K1, Palo
lto), 3 with MAD20-like block 2 sequences (Wellcome, MAD20,
d2), and R033 representing the R033-like block 2 type that has
inimal subtypic polymorphism. Each was identiﬁed and discrim-
nated by sequencing of MSP1 block 2. Parasite cultures were grown
nder standard conditions to a parasitemia of 4–10% (predomi-
antly schizont stage although asynchronous) and cells washed
wice after centrifugation before resuspension in PBS/1% BSA, for
reparation of IFA slides. Speciﬁc antibody reactivities to each of
he parasite isolates were assessed following previously described
ethods [22]. Parasites were air-dried onto multiwell IFA slides
Hendley, Essex, UK), ﬁxed with 4% formaldehyde and tested with
erial doubling dilutions of murine sera (1/50 to 1/409,600) in
BS with 1% bovine serum albumin (15 l/well) and incubated
or 30 min. Biotinylated anti-mouse or anti-rabbit IgG (Vector
aboratories Inc., California, USA) was used as the secondary anti-
ody at a 1/500 dilution and incubated for 30 min, followed by
 ﬁnal 30 min  incubation with ﬂuorescein-labeled streptavidin
Vector Laboratories, Inc., California, USA) at 1/500. Slides were
ounted in Vectashield mounting medium with 4′,6′-diamidino-2-
henylindole (DAPI) (Vector Laboratories, Inc., California, USA) and
xamined with a Nikon eclipse E600 ﬂuorescence microscope with
00× oil immersion objective and 10× eyepiece. Endpoint titre for
ach serum was deﬁned as the highest dilution that resulted in
right and clear schizont-speciﬁc ﬂuorescence.
.7. Enzyme-linked immune-sorbent assay (ELISA)Sera from immunized mice and rabbits were assayed for reactiv-
ty to recombinant GST-fusion proteins previously described [23]
epresenting each of the three MSP1 block 2 allelic types, 3D7robing with murine antiserum raised to the 3D7 block 2 repeat antigen (not shown)
 (kDa) markers are shown to the left.
(K1-like),  Wellcome (MAD20-like), and R033 by ELISA following
methods previously outlined in detail [15,24]. Brieﬂy, Immulon
4HBX ﬂat bottomed plates (Dynex Technologies inc.) were coated
with 50 ng/well of each recombinant protein in 100 l of coat-
ing buffer (15 mM Na2CO3, 35 mM NaHCO3; pH 9.3). Plates were
incubated overnight at 4 ◦C, washed with PBS-T (PBS with 0.05%
Tween), blocked (1% skimmed milk in PBS-T) for 5 h and washed
again. Sera were diluted (1/1000 for murine sera and 1/2000 for
rabbit sera) in blocking buffer, and 100 l volumes were aliquoted
in duplicate into antigen coated wells and incubated overnight at
4 ◦C. Plates were washed and wells incubated with either rabbit
anti-mouse (P0260, Dako UK) (1/5000 dilution) or swine anti-
rabbit HRP-conjugated IgG (P0399, Dako UK) (1/4000 dilution)
for 3 h at room temperature. Plates were washed and developed
with O-phenylenediamine dihydochloride (OPD) using SigmaFast
OPD tablets (Sigma, UK). Detection of mouse IgG subclasses fol-
lowed the same protocol, except biotin-conjugated polyclonal goat
anti-mouse antibodies to murine IgG subclasses were used as the
secondary antibody (Cambridge Bioscience, UK), followed by detec-
tion with HRP-conjugated streptavidin (Sigma, UK).
3.  Results
3.1. Conﬁrmation of antigenic composition of the polyvalent
hybrid proteins
All  six new recombinant proteins (Fig. 1A) were expressed as
soluble products that appeared as single bands on SDS-PAGE gels
(Fig. 1B), and Western blots were probed with speciﬁc polyclonal
sera previously raised to GST-expressed proteins expressing the K1
Super Repeat [15] and individual block 2 alleles [23] (Fig. 1C). The
individual sera reacted with predicted speciﬁcity against the differ-
ent hybrid antigens, verifying the modular antigenic composition of
each hybrid construct. The yield for the full polyvalent hybrid pro-
tein (antigen 6) averaged ∼13 mg/l of culture, and the lyophilized
7814 K.K.A. Tetteh, D.J. Conway / Vaccine 29 (2011) 7811– 7817
Fig. 2. Development of parasite speciﬁc IgG responses after immunization of groups
of ﬁve CD-1 outbred mice with each of the 6 polyvalent hybrid proteins (antigens
1–6  as shown in the scheme in Fig. 1A). Mean OD values for each group of mice are
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Fig. 3. Murine immunoglobulin subclass ELISA showing the mean (+S.D.) reactivities
as  OD values of sera from groups of ﬁve mice immunized with the polyvalent hybrid
proteins (antigens 1–6 as shown in the scheme in Fig. 1A), assayed at 1/1000 dilutionhown for sera from each time point assayed by ELISA at 1/1000 dilution against
ST-fusion  proteins representing each of the major allelic types of MSP1 block 2:
A) 3D7 (K1-like), (B) R033, (C) Wellcome (MAD20-like).
roduct was stable at temperatures ranging from −20 to 56 ◦C for
t least 3 weeks.
.2.  Immunogenicity of the polyvalent hybrid proteins
CD-1 outbred mice were immunized with each of the 6 hybrid
onstructs (antigens 1–6, Fig. 1A) in Alum. ELISAs were performed
o determine IgG antibody reactivities against different GST-fusion
roteins (MSP1 block 2 of 3D7, R033 and Wellcome alleles) [11] in
era collected from the mice at days 0, 14, 42 and 70 post immuniza-
ion. The full polyvalent hybrid protein (antigen 6) elicited strong
ntibody responses against each of the three types of block 2 pro-
eins, with overall higher titres and broader speciﬁcity than those
licited by the comparative polyvalent proteins (Fig. 2). Antigens
hat did not contain the T helper cell epitopes elicited minimal
esponses to the block 2 antigens except for antigen 5 that elicited
ome response to the 3D7 and R033 antigens. As with the murine
esponses, sera from each of ﬁve rabbits immunized with the full
olyvalent hybrid protein showed antibody reactivity against eachagainst the full polyvalent hybrid protein (antigen 6). Sera were from the ﬁnal bleed
(day 70) and mice that were immunized with adjuvant only are compared as ‘NEG’
controls.
of the 3D7, R033 and Wellcome block 2 recombinant antigens when
tested by ELISA (data not shown).
To test if there was a skew towards particular murine IgG sub-
class responses, each serum was  tested against the full polyvalent
hybrid protein (antigen 6) by ELISA. The responses elicited by each
of the six immunizing antigens contained a predominance of IgG1
and IgG2a, rather than IgG2b or IgG3 (Fig. 3).
3.3. Immunoﬂuorescence assay of different parasite lines
Murine  antibodies induced by each polyvalent hybrid protein
were tested against cultured P. falciparum lines each contain-
ing a distinct block 2 allelic type, 3D7 (K1-like allele), Wellcome
(MAD20-like), and R033 (Fig. 4A–F, respectively showing titres in
animals immunized with antigens 1–6). Murine antibody responses
to the full polyvalent hybrid protein (antigen 6) showed high titre
reactivity by IFA to the three different parasite isolates (Fig. 4F).
Mice immunized with the remaining ﬁve comparative polyvalent
antigens produced antibodies reactive with at least one block 2
allele, but failed to achieve a similar high titre response against
all three isolates (Fig. 4A–E). Antigens 2, 4 and 5, each missing
the N-terminal T-cell epitopes, elicited poor antibody responses,
although these were higher against R033 than against the other
isolates (Fig. 4B, D and E).
Sera  from rabbits immunized with antigen 6 were tested against
an expanded panel of 10 P. falciparum isolates with more diverse
alleles (containing more representatives of the K1-like and MAD20-
like types) (Fig. 5). Each of the ﬁve sera showed strong IFA reactivity
against all isolates, with titres ranging from 1/3200 to 1/1,638,400
(Fig. 5). The titres were expected to be higher than those elicited in
the mice, due to the use of a multiple immunization schedule with
Freund’s adjuvant in the rabbits.
4. Discussion
Antigenic diversity and poor immunogenicity of candidate
malaria antigens present signiﬁcant hurdles for the development
of malaria vaccines. Inadequate design could potentially lead to
survival and selection of parasites with heterologous alleles not
covered by a vaccine construct [25,26]. Hybrid recombinant pro-
tein subunit vaccines are one promising approach to circumventing
these hurdles. Hybrid proteins as malaria vaccines have been advo-
cated when combining two  or more unrelated proteins [27–29].
K.K.A. Tetteh, D.J. Conway / Vaccine 29 (2011) 7811– 7817 7815
Fig. 4. IFA endpoint titres of antisera from mice immunized with each of the six polyvalent hybrid proteins against schizonts of 3 P. falciparum lines, 3D7, R033, and Wellcome.
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+)T-3D7-R033-Wellcome; D, (−)T-3D7-R033-Wellcome; E, (−)T-K1SR-R033-Wellc
bove  the groups of ﬁve individual mouse sera.
owever, multi-allelic formulations for individual antigens have
ntil now involved mixture of different allelic protein components,
lthough viral vectors expressing a fusion of different allelic types
how promise, as illustrated by work on the apical merozoite anti-
en 1 [30–33].
We  describe the ﬁrst polyvalent hybrid protein immunogen to
e shown capable of eliciting a broad, high titre antibody reper-
oire against all major alleles of a highly polymorphic malaria
ntigen, in this case the block 2 region of MSP1 in P. falciparum.
era of all immunized mice and rabbits recognized puriﬁed allelic
ecombinant antigens and schizonts of diverse parasite isolates
y IFA. Importantly, incorporation of a complex composite repeat
equence to cover subtypic variation within the K1-like type [15]
id not reduce the titres of antibodies to the other components.
To  enhance the development of high titre antibodies to the poly-
alent hybrid we included two previously described T-cell epitopes
ig. 5. Log IFA endpoint titres of antisera from rabbits immunized with the full polyvalen
.  falciparum lines. The IFA titres for individual ﬁnal bleed rabbit antisera (animals 1–5) 
black bars), R033 (white bars) and MAD20-like (grey bars).lyvalent antigens 1–6 respectively: A, (+)T-3D7-R033; B, (−)T-R033-Wellcome; C,
, (+)T-K1SR-R033-Wellcome. The geometric mean titres of each group are indicated
located  within the N-terminal region of MSP1 [21,34]. By compar-
ing antibody titres elicited by the modular sub-component antigens
with the full polyvalent construct, it was  evident that inclusion
of the T-cell epitopes signiﬁcantly enhanced the immunogenicity.
Mice immunized with each of the constructs elicited a mixed sub-
class IgG1 and IgG2a response, suggesting the involvement of T
helper cells of both Th1 and Th2 subsets. Such responses are gener-
ally adjuvant dependant [35,36], and the murine responses in this
study were obtained with Alum that is suitable for human use.
Further  work on the candidacy of this immunogen is warranted,
which could include prime-boost experiments testing immuno-
genicity of the polyvalent sequence engineered in viral vectors as
well as in the protein form described here [33,37]. It would be ideal
to also have a validated assay that could be applied to test ani-
mal antibodies for parasite growth inhibition [38,39], but inhibitory
effects of antibodies to MSP1 block 2 appear to require co-operation
t protein (antigen 6, (+)T-K1SR-R033-Wellcome), against schizonts of a panel of 10
are shown against the panel of parasites with MSP1 block 2 types that are K1-like
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ith monocytes [13] in an assay that is challenging to standard-
se and replicate in different laboratories [39]. In contrast, direct
nhibitory effects of anti-MSP1 block 2 antibodies alone have gen-
rally not been detected [13] except in one report of a monoclonal
ntibody used at high concentration [20], and our attempts using
ell deﬁned allele-speciﬁc rabbit antibodies unexpectedly showed
on-allele-speciﬁc inhibition when tested against a panel of para-
ite isolates (data not shown). We  anticipate that new approaches
ay allow further development of sensitive and speciﬁc tests for
irect inhibitory effects of antibodies in the future [40]. Currently,
s a pre-clinical test of the efﬁcacy of this vaccine candidate, it
ould be most valuable to perform small scale immunization and
hallenge experiments in a new world monkey model as has been
sed to evaluate other individual antigens [32,41–44]. In addition
o the development of a candidate for further testing, this study
llustrates an approach that could be employed in the design of
olyvalent immunogens based on other antigens with complex
llelic polymorphisms.
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